Source: Zacks Investment Research News Agency
1 month ago•
Stock Medium Importance
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago.
Related Symbols 1
TVTX TVTX
Source: Zacks Investment Research
Visit Source
0 0 0
Comment
Comments
0
No comments yet
Be the first person to comment on this news item.